Literature DB >> 22689506

Chemokine CXCL12 and its receptors in the developing central nervous system: emerging themes and future perspectives.

Yan Zhu1, Fujio Murakami.   

Abstract

Homeostatic chemokine CXCL12 (also known as SDF-1) and its receptor CXCR4 are indispensable for the normal development of the nervous system. This chemokine system plays a plethora of functions in numerous neural developmental processes, from which the underlying molecular and cellular mechanisms are beginning to be unravelled. Recent identification of CXCR7 as a second receptor for CXCL12 provides opportunities to gain deeper insights into how CXCL12 operates in the nervous system. Here, we review the diverse roles of CXCL12 in the developing central nervous system, summarize the recent progress in uncovering CXCR7 functions, and discuss the emerging common themes from these works and future perspectives.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689506     DOI: 10.1002/dneu.22041

Source DB:  PubMed          Journal:  Dev Neurobiol        ISSN: 1932-8451            Impact factor:   3.964


  17 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands.

Authors:  Anthony P Davenport; Stephen P H Alexander; Joanna L Sharman; Adam J Pawson; Helen E Benson; Amy E Monaghan; Wen Chiy Liew; Chidochangu P Mpamhanga; Tom I Bonner; Richard R Neubig; Jean Philippe Pin; Michael Spedding; Anthony J Harmar
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

2.  Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke.

Authors:  Karsten Ruscher; Enida Kuric; Yawei Liu; Helene L Walter; Shohreh Issazadeh-Navikas; Elisabet Englund; Tadeusz Wieloch
Journal:  J Cereb Blood Flow Metab       Date:  2013-05-01       Impact factor: 6.200

Review 3.  Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain.

Authors:  Geeta Ramesh; Andrew G MacLean; Mario T Philipp
Journal:  Mediators Inflamm       Date:  2013-08-12       Impact factor: 4.711

Review 4.  CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.

Authors:  Roberto Würth; Adriana Bajetto; Jeffrey K Harrison; Federica Barbieri; Tullio Florio
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

5.  [(18)F]DPA-714 PET imaging of AMD3100 treatment in a mouse model of stroke.

Authors:  Yu Wang; Xuyi Yue; Dale O Kiesewetter; Zhe Wang; Jie Lu; Gang Niu; Gaojun Teng; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2014-09-04       Impact factor: 4.939

Review 6.  Pituitary Adenoma and the Chemokine Network: A Systemic View.

Authors:  Fabio Grizzi; Elena Monica Borroni; Alessandro Vacchini; Dorina Qehajaj; Manuela Liguori; Sanja Stifter; Maurizio Chiriva-Internati; Antonio Di Ieva
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-11       Impact factor: 5.555

Review 7.  The role of chemokines in hepatitis C virus-mediated liver disease.

Authors:  Anette Brass; Erwin Daniel Brenndörfer
Journal:  Int J Mol Sci       Date:  2014-03-18       Impact factor: 5.923

8.  Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells.

Authors:  Bianca Borchin; Joseph Chen; Tiziano Barberi
Journal:  Stem Cell Reports       Date:  2013-11-27       Impact factor: 7.765

Review 9.  Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.

Authors:  Federica Barbieri; Stefano Thellung; Roberto Würth; Federico Gatto; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Endocrinol       Date:  2014-11-17       Impact factor: 3.257

10.  Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease.

Authors:  Rina Zilkha-Falb; Nathali Kaushansky; Naoto Kawakami; Avraham Ben-Nun
Journal:  J Neuroinflammation       Date:  2016-01-08       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.